STOCK TITAN

Opko Health Inc. - OPK STOCK NEWS

Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.

OPKO Health Inc. (NASDAQ: OPK) is a diversified healthcare company focused on establishing leading positions in large, rapidly growing markets. OPKO operates through two main segments: Diagnostics and Pharmaceuticals.

OPKO's Diagnostics segment includes BioReference Laboratories, the nation's third largest clinical laboratory. BioReference offers a comprehensive range of diagnostic services and features a core genetic testing business supported by a skilled 400-person sales and marketing team. Notable products include the 4Kscore® test for prostate cancer and the Claros® 1 in-office immunoassay platform.

The Pharmaceutical segment of OPKO showcases a diverse portfolio of products. Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D insufficiency, was launched in November 2016. Other significant pharmaceutical developments include Varubitm for chemotherapy-induced nausea and vomiting, OPK88004 for type 2 diabetes and obesity, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia, both of which are in Phase 2 clinical trials.

OPKO has recently made headlines with strategic collaborations and technological advancements. BioReference Health, a subsidiary of OPKO, has entered a strategic alliance with SOPHiA GENETICS to incorporate MSK-ACCESS® liquid biopsy technology. This partnership aims to enhance BioReference's genomic analysis capabilities and offer state-of-the-art cancer testing across the U.S. Another collaboration with Prognos Health aims to merge genomic data with real-world data, facilitating precision medicine and improving patient outcomes.

Financially, OPKO continues to exhibit a strong performance with ongoing projects and strategic acquisitions. The acquisition of select assets from BioReference Health by Labcorp is set to expand OPKO's reach and capabilities, strengthening its market presence.

Headquartered in Miami, Florida, OPKO Health is committed to improving healthcare through innovation, scientific expertise, and strategic partnerships. For more detailed information about their products, services, and latest news, visit www.opko.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
covid-19

FAQ

What is the current stock price of Opko Health (OPK)?

The current stock price of Opko Health (OPK) is $1.56 as of September 6, 2024.

What is the market cap of Opko Health (OPK)?

The market cap of Opko Health (OPK) is approximately 1.1B.

What does OPKO Health Inc. specialize in?

OPKO Health Inc. specializes in diagnostics and pharmaceuticals, focusing on genetic testing and treatments for chronic diseases.

What are the main products offered by OPKO Health?

Key products include the 4Kscore® prostate cancer test, Rayaldee for secondary hyperparathyroidism, and Varubitm for chemotherapy-induced nausea.

What recent collaborations has OPKO Health announced?

OPKO Health's BioReference Health has partnered with SOPHiA GENETICS for genomic analysis and Prognos Health for real-world data integration.

Where is OPKO Health headquartered?

OPKO Health is headquartered in Miami, Florida.

What is the significance of the 4Kscore® test?

The 4Kscore® test is a blood test that helps assess the risk of aggressive prostate cancer, aiding in early detection and treatment planning.

How does BioReference Laboratories fit into OPKO Health's operations?

BioReference Laboratories is a key component of OPKO's diagnostics segment, offering comprehensive clinical and genetic testing services.

What is Rayaldee used for?

Rayaldee is used to treat secondary hyperparathyroidism in patients with stage 3-4 chronic kidney disease and vitamin D insufficiency.

What impact will the Labcorp acquisition have on OPKO Health?

The acquisition will expand OPKO's capabilities and market reach, enhancing its diagnostic services and overall market presence.

What are the future goals of OPKO Health?

OPKO aims to establish industry-leading positions in rapidly growing markets by leveraging its innovative technologies and strategic partnerships.

How can investors learn more about OPKO Health's performance?

Investors can visit OPKO's official website at www.opko.com for detailed information on financial performance, product updates, and strategic initiatives.

Opko Health Inc.

Nasdaq:OPK

OPK Rankings

OPK Stock Data

1.08B
697.38M
52.78%
27.11%
12.52%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States of America
MIAMI